Overview
Lung cancer is the leading cause of cancer related mortality. At present, surgical treatment is the main choice for early-stage lung cancer. Even after surgery, the 5-year recurrence rate is still as high as 18.4%-24%. Traditional Chinese medicine combined with thermal and cold ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to evaluate the efficacy of traditional Chinese medicine combined with thermal and cold ablation for patients with stage I non-small cell lung cancer.
Eligibility
Inclusion Criteria:
- The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good.
- Patients with lung nodule.
- Maximum diameter of lung nodule ≥8mm.
- The pathology of lung nodules biopsy was non-small cell lung cancer.
- I period according to the eighth edition of the TNM staging period.
- No mediastinal lymph node metastasis.
- Eastern Cooperative Oncology Group performance status of 0 to 1.
- No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
- Sufficient organ functions.
Exclusion Criteria:
- Patients with previous use of various hormones, immunosuppression or autoimmune diseases.
- Women during pregnancy or breast-feeding.
- Patients with severe heart, lung, kidney disease or other systemic diseases
- Patients with severe hemorrhagic diseases.
- Patients with a history of drug abuse or mental illness.
- Other conditions that the investigator has determined are not suitable for participation in this study
